pretickt

Is ALNY a good stock to buy?

Alnylam Pharmaceuticals, Inc. · end-of-day data as of Nov 13, 2026

Alnylam
ALNY · $22.11B
$165.04+5.4%
Nov 13, 2026 · close
$150$200$250SepOctNov9:3016:003 months -27.8%Nov 13 · close
▲ 6
  • PT$352.61 +113.7%
  • ConsensusBuy · 31
  • P/E vs own-89.5%
  • P/E vs sector-74.1%
  • Insiders$144K
  • Sector▲ +15.9%
Neutral
  • Earnings in90d
  • P/E8.3x
  • RSI35
  • Resistance+34.9%
  • Off 52w high-65.6%
  • Volume1.1x
  • Bollingerlower half
  • News0.00
  • FCF yield+2.3%
  • 52w range$149–$480
  • ATR+6.4%
  • Off ATH-66.7%
▼ 3
  • Trendbearish
  • MAs0 of 4
  • MACD-0.89

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Alnylam a good stock to buy?

Alnylam is strong on 3 of the 5 questions about the business; weak on execution. Alnylam's P/E ratio is 8.3 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage hard to copy
  3. Economics profitable
  4. Execution misses
  5. Fragility sturdy
  6. Price below its peers
DemandDo people want more of what it sells?growing

ALNY sales growth revenue growth

+53%a year, for the last 3 years

Alnylam's sales grew 53% a year for 3 years, to $3.71B in fiscal 2025.

ALNY analysts' forecast revenue estimates

+46%the sales they expect next fiscal year, on the last

Analysts expect Alnylam's sales to grow 46% to $5.44B in fiscal 2026 (21 analysts).

ALNY competitors

pretickt analysis+56%its sales in 12 months, on a year before

Alnylam's sales grew 56% in the 12 months to Sep 30, 2026, faster than Incyte (+25%), Twist Bioscience (+22%), Moderna (+14%) and Bio-Techne (+1%).

ALNY sales by business revenue by segment

62%of its sales from AMVUTTRA

AMVUTTRA brought Alnylam 62% of its sales in fiscal 2025; Net revenues from collaborations 15%.

Advantage moatIs it hard to copy?hard to copy

ALNY return on capital ROIC

pretickt analysis31%earned before tax on the money invested in it

Alnylam earned 31% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Incyte 29%, Bio-Techne 11%, Moderna -30% and Twist Bioscience -31%.

ALNY margin on each sale gross margin

77%left after making the product

Alnylam kept 77% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 59%.

EconomicsDoes it make good money?profitable

ALNY margin after costs profit margin

20%of sales left after running the business

Alnylam's operating margin was 20% in the 12 months to Sep 30, 2026, against -76% in fiscal 2022.

ALNY cash generated free cash flow

$501Mcash left after investing, last 12 months

Alnylam generated $501M of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.

ExecutionDoes it deliver what it promises?misses

ALNY earnings vs estimates

2 of 5quarters above the analysts' estimate

Alnylam beat the analysts' profit estimate in 2 of 5 quarters, the latest on Jul 30, 2026; 3 quarters with one-time gains or charges are left out.

ALNY insider selling

-$31.8Msold, net, by its executives in 12 months

Alnylam's executives and directors sold a net $31.8M of shares in the 12 months to Nov 13, 2026 ($32.34M sold, $543K bought).

ALNY number of employees

+12%more people in a year

Alnylam had 2,500 employees at the end of fiscal 2025, 12% more than a year before.

ALNY CEO pay

$14.87Mfor fiscal 2025, 66% of it in stock and options

Alnylam paid its CEO $14.87M for fiscal 2025, 66% of it in stock and options.

Fragility risksCould something break it?sturdy

ALNY financial health Altman Z-score

3.7Altman Z-score, safe above 3

Alnylam's Altman Z-score is 3.7 (Nov 13, 2026), above 3, where the safe zone starts.

ALNY quality checks Piotroski score

4 of 9checks passed

Alnylam passes 4 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on cash against profit, the current ratio, new shares, gross margin and sales for its assets.

ALNY biggest customers

45%of sales from its biggest customer

One customer, unnamed in Alnylam's 10-K, made 45% of its sales in fiscal 2025.

ALNY in past recessions

pretickt analysis+5%its sales in the worst one

Alnylam's sales grew through each of the last 2 US recessions (2008–09 and 2020).

Price valuationIs the price reasonable?below its peers

ALNY price vs profit P/E ratio

8.3×a year's earnings

Alnylam's P/E ratio is 8.3 (Nov 13, 2026).

ALNY price vs competitors

pretickt analysis8.3×a year's earnings, against its competitors

Investors pay 8.3 times Alnylam's earnings (Nov 13, 2026), less than for Bio-Techne (66.2) or Incyte (64.3).

ALNY analysts' target price target

+114%to their average target

Analysts' average price target for Alnylam is $353, 114% above the Nov 13, 2026 close of $165.04.

ALNY analyst ratings, 90 days

pretickt analysis
  • Bernsteindowngrade
  • Raymond Jamesdowngrade
  • Truist Securitiesdowngrade
0 up, 3 downratings raised and cut

In the 90 days to Nov 13, 2026, Bernstein, Raymond James and Truist Securities downgraded Alnylam.

ALNY growth priced in fair value

pretickt analysis+18%a year, for ten years, to be worth the price

At $165.04 a share, Alnylam's free cash flow must grow about 18% a year for ten years to be worth the price (Nov 13, 2026).

What is Alnylam's P/E ratio?

Alnylam's P/E ratio is 8.3 (Nov 13, 2026). Investors pay 8.3 times Alnylam's earnings (Nov 13, 2026), less than for Bio-Techne (66.2) or Incyte (64.3).

Who are Alnylam's biggest competitors?

pretickt compares Alnylam with Incyte, Bio-Techne, Twist Bioscience and Moderna. Alnylam's sales grew 56% in the 12 months to Sep 30, 2026, faster than Incyte (+25%), Twist Bioscience (+22%), Moderna (+14%) and Bio-Techne (+1%).

Is Alnylam profitable?

Alnylam's operating margin was 20% in the 12 months to Sep 30, 2026, against -76% in fiscal 2022. Alnylam generated $501M of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.

Are insiders selling Alnylam stock?

Alnylam's executives and directors sold a net $31.8M of shares in the 12 months to Nov 13, 2026 ($32.34M sold, $543K bought).

How does Alnylam make money?

AMVUTTRA brought Alnylam 62% of its sales in fiscal 2025; Net revenues from collaborations 15%.

How many employees does Alnylam have?

Alnylam had 2,500 employees at the end of fiscal 2025, 12% more than a year before.

Who are Alnylam's biggest customers?

One customer, unnamed in Alnylam's 10-K, made 45% of its sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.